Evidence map›Paper›PMID 33325595›Full record

ArticleThe oncologist2021

Survival Impact and Cost-Effectiveness of a Multidisciplinary Tumor Board for Breast Cancer in Mozambique, Sub-Saharan Africa.

Mariana Brandão, Assucena Guisseve, Genoveva Bata, João Firmino-Machado, Matos Alberto, Josefo Ferro, Carlos Garcia, Clésio Zaqueu, Astrilde Jamisse, Cesaltina Lorenzoni and 9 more

Registry-linked trialAbstract read
In one paragraph

Article in The oncologist, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06257888 (The Journey of Women With Breast Cancer in Mozambique), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06257888 completednot on this mapstarted 2024, after this paper: background citation

The Journey of Women With Breast Cancer in Mozambique: What is the Best Path? A Prospective Cohort With Patient Navigation as an Intervention to Reduce Treatment Disparities

TypeobservationalSponsorRenato Cagnacci NetoRan2024 to 2025Enrolled90ConditionsBreast Neoplasm Malignant PrimaryArmspatient navigation
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Mariana Brandão *EPIUnit - Instituto de Saúde Pública, Porto, Portugal.ORCID 0000-0002-1653-3544
Assucena Guisseve *Department of Pathology, Faculty of Medicine, University Eduardo Mondlane, Maputo, Mozambique.
Genoveva BataOncology, Maputo Central Hospital, Maputo, Mozambique.
João Firmino-MachadoEPIUnit - Instituto de Saúde Pública, Porto, Portugal.ORCID 0000-0001-9410-633X
Matos AlbertoDepartment of Pathology, Maputo Central Hospital, Maputo, Mozambique.
Josefo FerroDepartment of Pathology, Beira Central Hospital, Beira, Mozambique.
Carlos GarciaDepartment of Pathology, Beira Central Hospital, Beira, Mozambique.
Clésio ZaqueuDepartment of Pathology, Nampula Central Hospital, Nampula, Mozambique.
Astrilde JamisseRadiology, Maputo Central Hospital, Maputo, Mozambique.
Cesaltina LorenzoniDepartment of Pathology, Faculty of Medicine, University Eduardo Mondlane, Maputo, Mozambique.
Martine Piccart-GebhartInstitut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Dina LeitãoPatologia e Oncologia, Faculdade de Medicina, da Universidade do Porto, Porto, Portugal.
Jotamo ComeSurgical, Maputo Central Hospital, Maputo, Mozambique.ORCID 0000-0002-7084-743X
Otília SoaresOncology, Maputo Central Hospital, Maputo, Mozambique.
Alberto Gudo-MoraisOncology, Maputo Central Hospital, Maputo, Mozambique.ORCID 0000-0002-7016-7418
Fernando SchmittPatologia e Oncologia, Faculdade de Medicina, da Universidade do Porto, Porto, Portugal.ORCID 0000-0002-3711-8681
Satish TulsidásEPIUnit - Instituto de Saúde Pública, Porto, Portugal.ORCID 0000-0001-7613-6965
Carla Carrilho *EPIUnit - Instituto de Saúde Pública, Porto, Portugal.ORCID 0000-0003-0208-7309
Nuno Lunet *EPIUnit - Instituto de Saúde Pública, Porto, Portugal.ORCID 0000-0003-1870-1430

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite the international endorsement of multidisciplinary tumor boards (MTBs) for breast cancer care, implementation is suboptimal worldwide, and evidence regarding their effectiveness in developing countries is lacking. We assessed the impact on survival and the cost-effectiveness of implementing an MTB in Mozambique, sub-Saharan Africa. MATERIALS AND

methodsThis prospective cohort study included 205 patients with breast cancer diagnosed between January 2015 and August 2017 (98 before and 107 after MTB implementation), followed to November 2019. Pre- and post-MTB implementation subcohorts were compared for clinical characteristics, treatments, and overall survival. We used hazard ratios and 95% confidence intervals (CI), computed by Cox proportional hazards regression. The impact of MTB implementation on the cost per quality-adjusted life year (QALY) was estimated from the provider perspective.

resultsWe found no significant differences between pre- and post-MTB subcohorts regarding clinical characteristics or treatments received. Among patients with early breast cancer (stage 0-III; n = 163), the 3-year overall survival was 48.0% (95% CI, 35.9-59.1) in the pre-MTB and 73.0% (95% CI, 61.3-81.6) in the post-MTB subcohort; adjusted hazard ratio, 0.47 (95% CI, 0.27-0.81). The absolute 3-year mean cost increase was $119.83 per patient, and the incremental cost-effectiveness ratio was $802.96 per QALY, corresponding to 1.6 times the gross domestic product of Mozambique.

conclusionThe implementation of a MTB in Mozambique led to a 53% mortality decrease among patients with early breast cancer, and it was cost-effective. These findings highlight the feasibility of implementing this strategy and the need for scaling-up MTBs in developing countries, as a way to improve patient outcomes. IMPLICATIONS FOR PRACTICE: Currently, more than half of the deaths from breast cancer in the world occur in developing countries. Strategies that optimize care and that are adjusted for available resources are needed to improve the outcomes of patients with breast cancer in these regions. The discussion of cases at multidisciplinary tumor boards (MTBs) may improve survival outcomes, but implementation is suboptimal worldwide, and evidence regarding their effectiveness in developing countries is lacking. This study evaluated the impact of implementing an MTB on the care and survival of patients with breast cancer in Mozambique, sub-Saharan Africa and its cost-effectiveness in this low-income setting.

Indexed as

Breast NeoplasmsCost-Benefit AnalysisFemaleHumansMozambiqueProspective StudiesQuality-Adjusted Life YearsBreast neoplasmsCost-effectiveness analysisDeveloping countriesSub-Saharan AfricaSurvival analysis

Identifiers

PMID33325595
PMCPMC8176970

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.